Development of A Synergistic Novel Therapy against Antimicrobial Resistance Strains of <i>Helicobacter</i> <i>pylori</i>

Increasing Antimicrobial Resistance (AMR) compromises the treatment of Helicobacter pylori infection globally. This study aimed to use probiotics together with an antibiotic regimen and a proton pump inhibitor to eradicate H. pylori. Stools from positive Helicobacter pylori Stool Antigen (HpSAg), totaling 114 (47.7%) were cultivated on Columbia-based Dent agar (Oxoid) at different times. D Berg’s commercially sourced brand of Lactobacillus rhamnosus/casei probiotic was used. Following biochemical and molecular identification. A per-clinical-factorial-experimental design was employed for the study. Animals, aged 40 weeks old and above were prepared and grouped into six subsets labeled T1 - T6, each defining a particular experimental variable with n = 20. The H. pylori isolates 1 × 108 CFU/ml in normal saline were intraperitoneally administered to the test animals (T2 - T6) over 21 days. Different preparations of probiotics and antibiotics-probiotic therapies were given to the relevant subsets and the outcomes were monitored daily. Fisher’s exact software was used to calculate the error value at 5% (p H. pylori treatment lies in a good Antimicrobial Sensitivity Testing (AST) platform and that only a probiotic-antibiotic regimen can guarantee total eradication (100%) of H. pylori.